Original Article

Impact of small-quantity lipid-based nutrient supplement on hemoglobin, iron status and biomarkers of inflammation in pregnant Ghanaian women

Seth Adu-Afarwuah^{*}, Anna Lartey^{*}, Harriet Okronipa^{*}, Per Ashorn[†], Mamane Zeilani[‡], Lacey M. Baldiviez[§], Brietta M. Oaks[§], Stephen Vosti[§] and Kathryn G. Dewey[§]

^{*}Department of Nutrition and Food Science, University of Ghana, Accra, Ghana, [†]Center for Child Health Research and Department of Pediatrics, University of Tampere School of Medicine and Tampere University Hospital, Finland, [‡]Nutriset S.A.S., Malaunay, France, and [§]Program in International and Community Nutrition, Department of Nutrition, University of California, Davis, California, USA

Abstract

We examined hemoglobin (Hb, g/L), iron status (zinc protoporphyrin, ZPP, $\mu\text{mol/mol}$ heme, and transferrin receptor, TfR, mg/L) and inflammation (C-reactive protein, CRP and alpha-1 glycoprotein, AGP) in pregnant Ghanaian women who participated in a randomized controlled trial. Women ($n = 1320$) received either 60 mg Fe + 400- μg folic acid (IFA); 18 micronutrients including 20-mg Fe (MMN) or small-quantity lipid-based nutrient supplements (SQ-LNS, 118 kcal/d) with the same micronutrient levels as in MMN, plus four additional minerals (LNS) daily during pregnancy. Intention-to-treat analysis included 349, 354 and 354 women in the IFA, MMN and LNS groups, respectively, with overall baseline mean Hb and anemia (Hb <100) prevalence of 112 and 13.3%, respectively. At 36 gestational weeks, overall Hb was 117, and anemia prevalence was 5.3%. Compared with the IFA group, the LNS and MMN groups had lower mean Hb (120 ± 11 vs. 115 ± 12 and 117 ± 12 , respectively; $P < 0.001$), higher mean ZPP (42 ± 30 vs. 50 ± 29 and 49 ± 30 ; $P = 0.010$) and TfR (4.0 ± 1.3 vs. 4.9 ± 1.8 and 4.6 ± 1.7 ; $P < 0.001$), and greater prevalence of anemia (2.2% vs. 7.9% and 5.8%; $P = 0.019$), elevated ZPP (>60) [9.4% vs. 18.6% and 19.2%; $P = 0.003$] and elevated TfR (>6.0) [9.0% vs. 19.2% and 15.1%; $P = 0.004$]. CRP and AGP concentrations did not differ among groups. We conclude that among pregnant women in a semi-urban setting in Ghana, supplementation with SQ-LNS or MMN containing 20 mg iron resulted in lower Hb and iron status but had no impact on inflammation, when compared with iron (60 mg) plus folic acid (400 μg). The amount of iron in such supplements that is most effective for improving both maternal Hb/iron status and birth outcomes requires further evaluation. This trial was registered at ClinicalTrials.gov as: NCT00970866.

Keywords: lipid-based nutrient supplements, LNS, prenatal supplementation, multiple micronutrients, hemoglobin, iron status, inflammation.

Correspondence: Seth Adu-Afarwuah, Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana. E-mail: ct3665@gmail.com

Introduction

Poor nutrient intake during pregnancy has been associated with several adverse consequences. It is estimated that up to 50% of the anemia among pregnant women in many developing country settings is because of iron deficiency (van den Broek *et al.* 1998) usually as a result of low dietary iron intake (World Health Organization 1992) and poor iron bioavailability because of over-reliance on

plant-based diets high in inhibitors of iron absorption such as phytate (Tatala *et al.* 1998). Consequences of anemia include reduced work capacity and increased risk of mortality for the mother, and premature delivery, low birth weight and poor mental development for the infant (International Anemia Consultative Group (INACG) 2002; Ren *et al.* 2007). While normal pregnancy is found to be associated with an increased inflammatory response (Sacks *et al.* 1998; Picklesimer *et al.* 2008), this

response may be modified by macro- or micro-nutrients (Roberts *et al.* 2003). Higher intakes of folic acid (Bertran *et al.* 2005) and vitamin B6 (Friso *et al.* 2001) have been associated with lower concentration of C-reactive protein (CRP), a common biomarker of inflammation. Several other dietary factors including essential fatty acids, EFAs (Rallidis *et al.* 2003) and antioxidants (Devaraj & Jialal 2000; Brighenti *et al.* 2005) are also associated with the reduction of CRP concentration. Elevated CRP concentration in pregnancy is related to the development of pre-eclampsia and preterm delivery (Elovitz 2006).

A major recommendation for increasing nutrient intake among pregnant women in developing countries is the one developed by WHO (WHO, 2012), which is the consumption of iron/folic acid (IFA) supplements containing 30- to 60-mg iron and 400- μ g folic acid. In meta-analyses, this strategy, compared with no iron or placebo, reduced the risk of maternal anemia by 69–70% (Imdad & Bhutta 2012; Pena-Rosas *et al.* 2012) and iron deficiency by 57% (Pena-Rosas *et al.* 2012), but appeared to increase the risk of reported side effects (relative risk (RR) = 2.36; 95% CI: 0.96–5.82) particularly at iron doses of 60 mg or higher (Pena-Rosas *et al.* 2012). The WHO/UNICEF/UNU UNIMMAP (United Nations International Multiple Micronutrient Preparation) formulation containing 15 vitamins and minerals was more recently developed (UNICEF/WHO/UNU, 1999) to combat other possible deficiencies, e.g. for vitamins A, C and B12, which may also contribute to anemia (World Health Organization 1992). The dose

of iron in the UNIMMAP was set at 30 mg (below 60 mg) for the following reasons: (1) the presence of vitamins A, B2 and C in the UNIMMAP would enhance the absorption and utilization of iron, and therefore the lower amount of iron should be sufficient; (2) a lower iron dose would be associated with less negative side effects and therefore better adherence; (3) including 60 mg of iron would mean including at least 30 mg of zinc (to avoid possible negative influence of iron on zinc absorption), bringing the total amount of metals to 90 mg, which is likely to increase negative side effects; and (4) UNIMMAP may be used in conjunction with additional iron/folic acid tablets in individual cases of more severe anemia (assuming it is caused by iron deficiency). Meta-analyses suggested that supplementation with UNIMMAP and similar products (mostly containing 11 or more micronutrients including 30-mg iron) had the same effect on maternal hemoglobin (Hb) and iron status as iron (usually at 60-mg dose) with or without folic acid (Allen & Pearson 2009; Haider *et al.* 2011), while also reducing the risk of low birth weight (Fall *et al.* 2009; Haider & Bhutta 2012; Ramakrishnan *et al.* 2012).

Our group developed small quantity (20 g/d) lipid-based nutrient supplements (SQ-LNS) for pregnant and lactating women (Arimond *et al.* 2013) to provide micronutrients together with EFAs, using a minimum food base that supplies a small amount of energy (118 kcal/d) and high quality protein (2.6 g/d). In many populations, total energy intake among pregnant and lactating women may be adequate, but the EFA content of the usual diet may be low (Michaelsen *et al.* 2011). The micronutrient composition of the SQ-LNS

Key messages

- In this semi-urban Ghanaian population, the prevalence of anemia (Hb < 100 g/L) among pregnant women who received IFA, MMN or SQ-LNS was reduced from 13% at <20 gestational weeks (GW) to 5% at 36 GW.
- Provision of IFA (with 60 mg Fe) was associated with a greater mean concentration of Hb and lower prevalence of anemia at 36 GW than provision of MMN or SQ-LNS (both with 20 mg Fe).
- The prevalence of high Hb (> 130 g/L) or elevated inflammatory biomarkers (CRP and AGP) at 36 GW was not affected by the type of prenatal supplement provided.
- More research is needed to determine the concentration of iron in MMN and SQ-LNS supplements that is most effective for improving both maternal Hb/iron status and birth outcomes.

was generally based on the UNIMMAP formulation and a similar product used in Guinea Bissau (Kaestel *et al.* 2005), but we further reduced the daily iron dose to 20 mg, based on evidence that 20 mg day⁻¹ may be an adequate dose to prevent iron deficiency anemia (IDA) during pregnancy (even for women who are iron deficient at entry to prenatal care) and causes fewer gastrointestinal side effects, compared with higher doses of iron (Zhou *et al.* 2009). We estimated (Arimond *et al.* 2013) that in addition to iron coming from the usual diet, the 20 mg of iron from a daily supplement would meet the recommended dietary allowance (RDA) of 27 mg iron during pregnancy (and be close to the 30 mg/d dose in the UNIMMAP formulation) while not greatly exceeding the RDA (9 mg/d) for iron during lactation (IOM 2001; Arimond *et al.* 2013).

Currently, there is a growing interest in the potential use of Small-Quantity Lipid-based Nutrient Supplements (SQ-LNS) among pregnant women in developing-country settings (Research Engagement on Food Innovation for Nutritional Effectiveness (REFINE) 2013; Hambidge *et al.* 2014), because of evidence suggesting a positive impact of the product on certain pregnancy outcomes (Adu-Afarwuah *et al.* 2015). However, little is known about the impact of SQ-LNS on maternal outcomes such as anemia, iron status and inflammation. We previously reported (Adu-Afarwuah *et al.* 2015), that compared with IFA and a multiple micronutrient (MMN) capsule with most of the same micronutrients as the SQ-LNS, the SQ-LNS promoted fetal growth in vulnerable women, particularly primiparas, while the occurrence of serious adverse events did not differ between the three groups. In the current analysis, we compare the effect of the three supplementation regimens (IFA, MMN and SQ-LNS), on maternal Hb, iron status and two biomarkers of inflammation (CRP and alpha-1 glycoprotein, AGP) during pregnancy.

Methods

Study setting, design, participants and blinding

The iLiNS-DYAD study in Ghana was conducted in several adjoining semi-urban communities in the Yilo

Krobo and the Lower Manya Krobo Districts about 70 km north of Accra, Ghana. Details of the study setting, participants, design, randomization and masking schemes, and other key procedures have been reported elsewhere (Adu-Afarwuah *et al.* 2015). In brief, the study was designed as a partially double-blind, parallel, individually randomized, controlled trial with three equal-size groups. Pregnant women attending usual ante-natal clinics in four main health facilities in the area between December 2009 and December 2011 completed a screening questionnaire if they were ≥ 18 years old, ≤ 20 -week gestation (as determined by the antenatal clinics mostly by fundal height), and had an antenatal card complete with history and examination. Informed consent for the screening was obtained by trained study workers at the antenatal clinics. Following screening, women were excluded if the antenatal card indicated HIV infection, asthma, epilepsy, tuberculosis or any malignancy. Additional exclusion criteria were known milk or peanut allergy, not residing in the area, intention to move within the next 2 years, unwillingness to receive field workers or take study supplement, participation in another trial or gestational age (GA) > 20 weeks before completion of the enrolment process.

Women who passed the screening were visited in their homes, where details of the study were provided, and those willing to participate were recruited, after signing or thumb-printing informed consent. Recruited women remaining eligible underwent a baseline laboratory assessment after consent, and were immediately randomized to receive one of three treatments daily: (a) 60 mg iron plus 400- μ g folic acid (hereafter, IFA supplement or group); (b) multiple micronutrient capsule containing 18 vitamins and minerals (including 20 mg iron) (hereafter, MMN supplement or group); and (c) SQ-LNS with similar micronutrients as the MMN supplement, plus other minerals and macronutrients (hereafter, LNS supplement or group). Group allocations were developed by the Study Statistician at UC Davis using a computer-generated (SAS version 9.3) randomization scheme (in blocks of nine), and were placed in sealed, opaque envelopes. At each enrolment, a Study Nurse offered nine envelopes at a time, and the woman picked one to reveal the allocation. Allocation information was kept securely by the Field Supervisor and the Study Statistician only.

The compositions of the 3 supplements were reported previously (Adu-Afarwuah *et al.* 2015), as well as the considerations underlying the concentrations of the nutrients in the MMN and SQ-LNS (Arimond *et al.* 2013). Apart from iron which was kept at 20 mg/day in the MMN and SQ-LNS, the vitamin and mineral contents were either 1x or 2x the RDA for pregnancy, or in a few cases, the maximum amount that could be included in the supplement given technical and organoleptic constraints. The IFA and MMN supplements were provided as capsules in blister packs, and were intended to be consumed with water after a meal, one capsule per day throughout pregnancy. The LNS supplement was in 20-g sachets, and was intended to be mixed with any prepared food, one sachet per day throughout pregnancy. To maintain blinding, two individuals independent of the study placed color-coded stickers behind the blister packs (three different colors for IFA and three for MMN supplements) so that the capsules were known to the study team and participants only by the colors of the stickers. Laboratory staff and data analysts had no knowledge of group assignment until all preliminary analyses had been completed and the allocation codes were broken. The study was registered on ClinicalTrials.gov (Identifier: NCT00970866) and was approved by ethics committees of the University of California, Davis, the Ghana Health Service and the University of Ghana Noguchi Memorial Institute for Medical Research.

Procedures

We collected socio-demographic information at baseline, and determined GA mostly by ultrasound biometry (Aloka SSD 500, Tokyo, Japan). During follow-up, field workers visited women in their homes every 2 weeks, whereupon they delivered a fresh supply of supplement and monitored supplement intakes. At each of laboratory assessments at baseline and at 36 GW, women's weight (Seca 874) and height (Seca 217) were measured, and peripheral malaria parasitemia (Clearview Malarial Combo, Vision Biotech, South Africa), Hb (HemoCue AG, Wetzikon, Switzerland) and zinc protoporphyrin, ZPP (hematofluorometer, Aviv Biomedical Co. NJ, USA), were determined using venous blood (Adu-Afarwuah

et al. 2015). We used the original Aviv cover-slides and three-level control material for the ZPP measurements, after red blood cells were washed three times with normal saline. Plasma samples obtained after blood was centrifuged at 1252 ×g for 15 min were stored in Ghana at −20°C, before being air-freighted on dry ice to UC Davis, where soluble transferrin receptor (TfR, mg/L), CRP (mg/L) and AGP (g/L) concentrations were determined using a Cobas Integra 400 plus Automatic Analyzer (Roche Diagnostic Corp., Indianapolis, IN).

At 36 GW, the continuous outcome measures were Hb (g/L), ZPP (μmol/mol heme) and plasma TfR (mg/L), CRP (mg/L) and AGP (g/L) concentrations, while the binary outcome measures were the percentages of women with low Hb, high Hb and elevated ZPP, TfR, CRP and AGP.

Sample size and data analysis

For the Ghana iLiNS-DYAD Study, an effect size (Cohen's *d*: difference between group means divided by the pooled standard deviation) of 0.3 (considered a small-to-moderate effect size) (Cohen, 1988) was the basis for sample size calculation. Thus, our sample size was based on detecting an effect size of 0.3 between any two groups for any continuous variable at 36 GW, with a two-sided 5% test and 80% power. As described previously (Adu-Afarwuah *et al.* 2015), we enrolled 1320 pregnant women into the study, but after excluding 177 who received both IFA and MMN supplements during pregnancy because of a temporary mislabeling of supplements, as well as 86 in the LNS group who were pregnant during the same time period, 1057 women were included in the current analysis. Based on a sample size of 827 women (~275 per group) for whom data were available at 36 GW, we had 94% power to detect an effect size of 0.3 between any two groups for Hb, ZPP or TfR. This would allow a difference of 3.4 g/L in Hb, 8.9 μmol/mol heme in ZPP and 0.5 mg/L in TfR (given SD of 11.0, 30.0 and 2.0, respectively) to be detected between any two groups.

We posted the statistical analysis plan (www.ilins.org) before analysis. Statistical analysis, by intention-to-treat, was performed using SAS for Windows Release 9.3 (Cary, NC, USA). Background socio-

demographic characteristics were summarized as mean $\pm$ SD for continuous variables, or number of participants and percentages for categorical variables. As done previously (Adu-Afarwuah *et al.* 2015), we used two indices, namely assets index and housing index as proxy indicators for socioeconomic status, and calculated household food insecurity access (HFIA) score (Coates *et al.* 2007) as a measure of degree of household food insecurity. Higher values of the assets and housing indices represented higher socioeconomic status, and higher values of the food insecurity index represented higher food insecurity.

We calculated adherence to treatment as percentage of days from enrolment to the home visit closest to the laboratory assessment at 36 GW, when women reported consuming the supplement. We used Hb <100 g/L as our primary definition for low Hb (representing anemia). This was based on previous WHO (WHO/UNICEF/UNU 2001; WHO 2007) and International Nutritional Anemia Consultative Group, INACG (Nestle & INACG Steering Committee 2002) documents that suggest lowering the standard 110 g/L cut-off by 10 g/L for pregnant women of African extraction to achieve adequate sensitivity and specificity for screening purposes (WHO/UNICEF/UNU 2001). In addition, we defined low Hb using the standard cut-off of Hb <110 g/L, based on a recent WHO recommendation (WHO 2011) to maintain that cut-off (110 g/L) without any adjustment, because of scarce evidence to support the adjustment. A meta-analysis (Haider *et al.* 2013) revealed that Hb cut-offs ranging from <100 g/L to 115 g/L have been used in studies to define anemia in pregnant women. We defined high Hb as >130 g/L (Pena-Rosas *et al.* 2012), elevated ZPP (proxy for iron deficiency) as >60 μ mol/mol heme (Walsh *et al.* 2011) and elevated TfR (proxy for tissue iron deficiency) as >6.0 mg/L (Pfeiffer *et al.* 2007; Vandevijvere *et al.* 2013). Because there is no generally accepted cut-off value for TfR, we derived the 6.0 mg/L cut-off based on the evidence that TfR values obtained using the Automatic Analyzer assay (as used in this study) were on average 30% lower than values obtained with the ELISA assay (Pfeiffer *et al.* 2007). Therefore, we reduced by 30% the 8.5 mg/L cut-off value used when TfR was determined

using ELISA (Vandevijvere *et al.* 2013) to obtain the cut-off of approximately 6.0 mg/L for our analysis. Because we used two cut-offs to define anemia, we also defined IDA in two ways: first as Hb <100 g/L and at least one marker of iron deficiency (ZPP >60 (μ mol/mol heme) or TfR >6.0 mg/L (Pfeiffer *et al.* 2007; Vandevijvere *et al.* 2013)), and second, as Hb <110 g/L and at least one marker of iron deficiency. We defined elevated inflammatory markers using the cut-off values of >5.0 mg/L for CRP and >1.0 g/L for AGP (Thurnham and McCabe, 2012), and categorized women with inflammation as either elevated CRP only (indicative of incubation phase of infection), elevated CRP and AGP (indicative of early convalescence) or elevated AGP only (indicative of late convalescence) (Thurnham and McCabe, 2012).

At 36 GW, we calculated overall mean ($\pm$ SD) values and percentages for Hb and markers of iron status and inflammation. We compared groups by using general linear models (continuous outcomes) and logistic regression models (binary), with Tukey–Kramer adjustment for multiple comparisons. Along with the group comparisons, we calculated pairwise mean differences (continuous outcomes, ANOVA) and relative risks (binary outcomes, Logistic regression) with their 95% CI and *P*-values. Relative risks were calculated using Poisson regression (Spiegelman & Hertzmark 2005). In addition, we analyzed changes in the prevalence of anemia, high Hb and elevated ZPP, TfR, CRP and AGP from enrolment using mixed model logistic regression (SAS PROC GLIMMIX). Where the mixed model logistic regression failed to converge because of sparse data, we used generalized estimating equations model (SAS PROC GENMOD). We analyzed each outcome twice, first without any covariate adjustments, and then with adjustment for covariates significantly associated ($P < 0.10$) with the outcome in a bivariate analysis. Because ZPP, TfR, AGP and CRP are not normally distributed, we calculated the group means ($\pm$ SD or SE), group percentages and pair-wise mean differences and relative risks with their 95% CI based on untransformed data, but generated the *P*-values for group or pair-wise comparisons using logarithmically transformed data.

To investigate the possible effect of group differences in adherence to treatment, we performed

a per-protocol analysis, which was restricted to women with adherence $\geq 70\%$. We evaluated potential interaction of treatment group with pre-specified baseline variables for maternal characteristics, anemia and iron status. These variables were: age, years of schooling, BMI, gestational age at enrolment, household assets index, housing index, food insecurity access score, season at enrolment (dry or wet), primiparous, anemia and elevated ZPP, TfR, and AGP or CRP. Where an interaction was significant ($\alpha < 0.10$), we performed subgroup analysis by including an interaction term between treatment and the effect modifier in the ANCOVA or logistic regression model. For continuous effect modifiers, we used data from all participants to create a linear regression model to predict the values of the outcome at the 10th and 90th percentile of the effect modifier distribution. Each effect modifier was considered separately in the models to avoid collinearity.

In a sensitivity analysis aimed at correcting for the effect of inflammation (CRP and AGP) on the Hb and iron status outcomes, we repeated the above analyses using values of Hb and iron status markers corrected for inflammation (WHO 2007). These corrected values were calculated by grouping women into three inflammation categories, estimating the correction factor (CF) for each inflammation category, and multiplying the Hb and iron status values of each woman by the inflammation category-specific CF (Grant *et al.* 2012). The three inflammation categories were: reference (normal CRP and AGP), incubation (raised CRP and normal AGP) and early (raised CRP and AGP) or late (normal CRP and raised AGP) convalescence [these two phases of convalescence were combined because of small sample sizes and little indication of differences]. For ZPP at 36 GW, women were grouped into two inflammation categories (normal vs. any inflammation), because the three-category grouping did not yield consistent results.

Results

We collected data from December 2009 to August 2012. The study flow diagram, as well as the main

reasons women were not eligible, or were eligible but not enrolled, was reported elsewhere (Adu-Afarwuah *et al.* 2015). Among eligible women, those enrolled ($n = 1320$) and those not enrolled ($n = 606$) did not differ in most background characteristics (results not shown). The background characteristics of the 1057 women included in the current analysis are presented in **Table 1**. These characteristics were well balanced across the three groups. On average, women were about 26 years of age, had about 7 years of formal education and BMI of about 25 kg/m^2 . Nearly all of the women said they were married or living with a partner, slightly more than a third were primiparous, and nearly 10% tested positive for malaria. The average GA at enrolment was 16 weeks. At baseline, we obtained Hb values for all 1057 women, ZPP values for 1055 women, and TfR, CRP and AGP values for 1032 women.

At 36 GW, dropout (4.4%) was low, and did not differ among groups ($P = 0.65$). Women who dropped out – mainly because of miscarriage (2.8%) and movement from the study site (1.2%) – did not differ in the baseline characteristics from those who were present at 36 GW, except for GA (weeks) at enrolment, which was significantly lower ($P = 0.001$) for the former (14.5) than for the latter (16.3). Mean ($\pm$ SD) adherence (% of days from enrolment to the home visit closest to the laboratory assessment at 36 GW when supplement was reportedly consumed) was lower ($P = 0.001$) in the LNS group (68 ± 24) compared with the IFA (74 ± 21) and the MMN (72 ± 23) groups. Women usually reported mixing the LNS supplement with porridge, but sometimes mixed it with other foods including soups and stews, or consumed it alone. We obtained Hb values for 827 women, and ZPP, TfR, CRP and AGP values for 822 women; the number (%) of women without Hb values did not differ between groups ($P = 0.10$). The women with Hb values did not differ from those without Hb values in most of the baseline characteristics, except that the latter had lower mean housing index (-0.17 ± 1.09 vs. 0.04 ± 0.99 ; $P = 0.011$), BMI (24 ± 4.0 vs. $25 \pm 4.7 \text{ kg/m}^2$; $P = 0.022$) and GA at enrolment (16 ± 3.1 vs. 16 ± 3.3 weeks; $P = 0.042$).

In the intention-to-treat analysis, the overall mean ($\pm$ SD) values at baseline and 36 GW were 112 ± 12 and 117 ± 12 , respectively, for Hb (g/L), 45 ± 32 and

Table 1. Background characteristics of pregnant Ghanaian women whose hemoglobin, and iron status and inflammatory markers were analyzed at 36 gestational weeks, by intervention group*

Background characteristics	IFA (N = 349)	MMN (N = 354)	LNS (N = 354)
Age, y	27 ± 5.3 [349]	27 ± 5.7 [354]	27 ± 5.4 [354]
Formal education, y	7.6 ± 3.5 [349]	7.5 ± 3.6 [354]	7.7 ± 3.7 [354]
Body Mass Index, kg/m ²	25 ± 4.3 [342]	25 ± 5.0 [348]	25 ± 4.4 [349]
Low BMI, n/N (%)	11/342 (3.2)	8/348 (2.3)	6/349 (1.7)
Gestational age at enrolment, weeks	16.3 ± 3.3 [346]	16.2 ± 3.2 [353]	16.2 ± 3.3 [349]
Assets index [†]	0.09 ± 0.98 [342]	0.1 ± 0.9 [349]	−.01 ± 0.91 [348]
Housing index [†]	0.04 ± 0.99 [342]	−0.03 ± 1.03 [349]	0.00 ± 1.00 [348]
HFIA Score [‡]	2.9 ± 4.6 [345]	2.5 ± 3.9 [346]	2.5 ± 3.9 [348]
Married or co-habiting, n/N (%)	320/349 (91.7)	332/354 (93.8)	328/354 (92.7)
Primiparous women, n/N (%)	131/349 (37.5)	110/354 (31.1)	128/354 (36.2)
Tested positive for malaria [§] , n/N (%)	31/349 (8.9)	30/354 (8.5)	40/354 (11.3)

*IFA = Iron-Folic Acid group; MMN = Multiple Micronutrients group. LNS = Small Quantity Lipid-based Nutrient Supplement group. HFIA is Household Food Insecurity Access Score. N = total number of participants in the group in question; n = number of participants positive on the variable in question; % = percent of participants positive on the variable in question. Values are Mean ± SD [N] or n/N (%). [†]Proxy indicators for household socioeconomic status; higher values represent higher socioeconomic status. [‡]HFIA (Household food insecurity access) is a proxy indicator for household food insecurity (Coates *et al.* 2007); higher values represent higher food insecurity. [§]Rapid Diagnostic Test (Clearview Malarial Combo, Vision Biotech, South Africa).

47 ± 30 for ZPP (μmol/mol heme) and 4.1 ± 2.5 and 4.5 ± 1.7 for TfR (mg/L). From baseline to 36 GW, the prevalence of anemia decreased significantly from 13% to 5.3% ($P < 0.001$), while the reverse was true for the prevalence of high Hb (4.9% vs. 12%, $P < 0.001$) and elevated TfR (9.2% to 15%; $P = 0.001$), with a moderate change in the prevalence of elevated ZPP (13% vs. 16%; $P = 0.06$). The mean (±SD) CRP (mg/L) and AGP (g/L) at baseline (6.9 ± 11 and 0.6 ± 0.2, respectively) were slightly greater than at 36 GW (5.7 ± 17 and 0.5 ± 0.2, respectively), which was also reflected in the percentages of women with elevated CRP and AGP at baseline vs. 36 GW (38.2% vs. 24.1%; $P < 0.001$ and 6.3% vs. 2.8%; $P < 0.001$, respectively).

Main group comparisons at 36 gestational weeks

Table 2 shows the unadjusted mean (±SD) Hb (g/L), ZPP (μmol/mol heme), TfR (mg/L), CRP (mg/L) and AGP (g/L) concentrations, by intervention group, at baseline and 36 GW in the intention-to-treat analysis. Baseline values did not differ significantly among groups. At 36 GW, mean Hb was significantly ($P < 0.001$) greater in the IFA group (120 ± 11) than in the LNS (115 ± 12) or MMN (117 ± 12) group; ZPP was significantly ($P < 0.001$) lower in the IFA group (43

± 30) than in the LNS (50 ± 29) or MMN (49 ± 30) group; and TfR was significantly ($P < 0.001$) lower in the IFA group (4.0 ± 1.3) than in the LNS (4.9 ± 1.8) or MMN (4.6 ± 1.7) group. Further (**Table 3**), the percentage of women with anemia defined either as Hb <100 g/L or Hb <110 g/L was significantly lower in the IFA group compared with the LNS and MMN groups, and when using the latter definition, this percentage was also significantly greater in the LNS compared with the MMN group. Compared with the IFA group, the LNS and MMN groups had greater percentages of women with elevated ZPP (9.4% vs. 19% and 19%, respectively; $P = 0.003$) and elevated TfR (9.0% vs. 19% and 15%, respectively; $P = 0.004$). Differences among the three groups in the prevalence of IDA were marginally significant ($P = 0.07$) when the Hb cut-off of 100 g/L was used in the definition of IDA, but were significant ($P < 0.001$) when the Hb cut-off of 110 g/L was used. In the latter situation, the risk of IDA was significantly greater in the LNS group compared with the IFA group ($P < 0.001$), and marginally greater in the MMN compared with the IFA group, and in the LNS compared with the MMN group. The prevalence of high Hb did not differ among groups ($P = 0.15$).

From baseline to 36 GW, the decrease in the prevalence of anemia (based on our primary definition of

Table 2. Unadjusted hemoglobin, and iron status and inflammatory markers of pregnant Ghanaian women at baseline and 36 gestational weeks, by intervention group, and pair-wise comparison of groups*

Variable	IFA [†]	MMN [†]	LNS [†]	<i>P</i> [‡]	Comparison of IFA and MMN		Comparison of IFA and LNS		Comparison of MMN and LNS		
	[<i>N</i> = 349]	[<i>N</i> = 354]	[<i>N</i> = 354]		Mean difference (95% CI)	<i>P</i>	Mean difference (95% CI)	<i>P</i>	Mean difference (95% CI)	<i>P</i>	
Hb, g/L											
Baseline	112 ± 13 [349]	111 ± 12 [354]	112 ± 12 [354]		−1 (−4, 1)		0 (−2, 2)		1 (−1, 3)		
36 GW	120 ± 11 [270]	117 ± 12 [291]	115 ± 12 [266]	<0.001	−3 (−6, −1)	0.002	−5 (−7, 3)	<0.001	−2 (−4, 1)	0.18	
ZPP, μmol/mol heme											
Baseline	43 ± 28 [347]	46 ± 36 [354]	45 ± 33 [354]		3 (−3, 8)		2 (−4, 8)		−1 (−6, 5)		
36 GW	42 ± 30 [267]	49 ± 30 [291]	50 ± 29 [264]	<0.001	6 (0, 12)	<0.001	7 (1, 13)	<0.001	1 (−5, 7)	0.91	
TfR, mg/L											
Baseline	4.0 ± 1.9 [338]	4.0 ± 1.7 [348]	4.3 ± 3.5 [346]		0.0 (−0.4, 0.5)		0.3 (−0.1, 0.8)		0.3 (−0.1, 0.8)		
36 GW	4.0 ± 1.3 [266]	4.6 ± 1.7 [291]	4.9 ± 1.8 [265]	<0.001	0.5 (0.2, 0.9)	<0.001	0.8 (0.5, 1.2)	<0.001	0.3 (−0.0, 0.6)	0.07	
CRP, mg/L											
Baseline	7.9 ± 14 [338]	5.8 ± 8.3 [348]	6.9 ± 11 [346]		−2.1 (−4.1, −0.1)		−1.1 (−3.1, 1.0)		1.0 (−1.0, 3.0)		
36 GW	5.6 ± 18 [266]	5.7 ± 14 [291]	5.9 ± 18 [265]	0.85	0.1 (−3.3, 3.5)	0.95	0.3 (−3.2, 3.8)	0.97	0.2 (−3.2, 3.6)	0.84	
AGP, g/L											
Baseline	0.7 ± 0.2 [338]	0.6 ± 0.2 [348]	0.6 ± 0.2 [346]		0.0 (−0.1, 0.0)		0.0 (−0.1, 0.0)		0.0 (0.0, 0.0)		
36 GW	0.5 ± 0.2 [266]	0.5 ± 0.2 [291]	0.5 ± 0.2 [265]	0.30	0.0 (0.0, 0.1)	0.65	0.0 (0.0, 0.0)	0.80	0.0 (−0.1, 0.0)	0.27	

*IFA = Iron-Folic Acid group; MMN = Multiple Micronutrients group; LNS = Small Quantity Lipid-based Nutrient Supplement group. AGP, CRP, GW, Hb, TfR and ZPP are alpha-1 acid glycoprotein, C-reactive protein, gestational weeks, hemoglobin, transferrin receptor and zinc protoporphyrin, respectively. Analyses are based on ANOVA (SAS, PROC GLM). Group means (±SD) and pair-wise mean difference (95% CI) were calculated using untransformed data. Except for Hb, all *P*-values for group or pair-wise comparisons were generated from log-transformed data; untransformed data were used for comparisons of mean Hb values. *N* = total number of participants in the group in question. [†]Values are Mean ± SD [N]. [‡]*P*-values, with Tukey–Kramer adjustments, compare all three groups.

Hb <100 g/L) and increase in the prevalence of high Hb were significant for all groups; the change in prevalence over time differed between groups for anemia (*P*-interaction = 0.099) but not for high Hb (*P*-interaction = 0.95). For elevated ZPP, the increase in prevalence from baseline was marginally significant in the LNS group (*P* = 0.06) and non-significant in the other two groups, and the change in prevalence over time did not differ between groups (*P*-interaction = 0.14). For elevated TfR, the increase in prevalence was significant for the LNS (*P* = 0.003) and MMN (*P* = 0.009) groups only, and the change in prevalence over time

did not differ between groups (*P*-interaction = 0.17). Apart from the prevalence of anemia defined using the Hb cut-off of 110 g/L, the LNS and MMN groups did not differ significantly in any of the continuous (Table 2) or binary (Table 3) Hb and iron status outcomes.

There were no significant differences among groups in 36 GW mean (±SD) concentrations of CRP (*P* = 0.98) and AGP (*P* = 0.35) (Table 2), or the percentages of women in the incubation phase of infection (elevated CRP only; *P* = 0.26), early convalescence (both CRP and AGP elevated; *P* = 0.67) or late convalescence (elevated AGP only; *P* = 1.00). From baseline

Table 3. Number (percentage) of pregnant Ghanaian women with abnormal hemoglobin, and iron status and inflammatory markers at baseline and 36 weeks of gestation, by intervention group and pairwise relative risks (RR) between groups*

	IFA [†] [N = 349]	MMN [†] [N = 354]	LNS [†] [N = 354]	P [‡]	Comparison of IFA and MMN [§]		Comparison of IFA and LNS [§]		Comparison of MMN and LNS [§]		
					RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	
Low Hb (<100 g/L) [‡]											
Baseline	39/349 (11.2)	51/354 (14.4)	47/354 (13.3)		1.29 (0.81, 2.05)		1.19 (0.74, 1.91)		0.92 (0.59, 1.43)		
36 GW	6/270 (2.2)	17/291 (5.8)	21/266 (7.9)	0.019	2.63 (0.88, 7.86)	0.09	3.55 (1.22, 10.3)	0.013	1.35 (0.65, 2.83)	0.60	
Low Hb (<110 g/L) [†]											
Baseline	139/349 (39.8)	157/354 (44.4)	134/354 (37.9)		1.11 (0.90, 1.37)		0.95 (0.76, 1.19)		0.85 (0.69, 1.06)		
36 GW	38/270 (14.1)	69/291 (23.7)	88/266 (33.1)	<0.001	1.68 (1.10, 2.59)	0.011	2.35 (1.56, 3.53)	<0.001	1.40 (1.01, 1.92)	0.038	
High Hb [‡]											
Baseline	21/349 (6.0)	15/354 (4.2)	16/354 (4.5)		0.70 (0.33, 1.52)		0.75 (0.35, 1.60)		1.07 (0.47, 2.43)		
36 GW	42/270 (15.6)	32/291 (11.0)	28/266 (10.5)	0.15	0.71 (0.42, 1.18)	0.25	0.68 (0.40, 1.16)	0.20	0.96 (0.54, 1.70)	0.98	
Elevated ZPP ^{¶¶}											
Baseline	40/347 (11.5)	54/354 (15.3)	46/354 (13.0)		1.32 (0.84, 2.09)		1.13 (0.70, 1.81)		0.85 (0.55, 1.32)		
36 GW	25/267 (9.4)	56/291 (19.2)	49/264 (18.6)	0.003	2.06 (1.21, 3.48)	0.003	1.98 (1.16, 3.40)	0.007	0.96 (0.64, 1.46)	0.98	
Elevated TTR ^{††}											
Baseline	29/338 (8.6)	29/348 (8.3)	37/346 (10.7)		0.97 (0.54, 1.75)		1.25 (0.72, 2.17)		1.28 (0.74, 2.23)		
36 GW	24/266 (9.0)	44/291 (15.1)	51/265 (19.2)	0.004	1.68 (0.96, 2.94)	0.08	2.13 (1.24, 3.67)	0.003	1.27 (0.82, 1.97)	0.40	
IDA ^{‡‡}											
Baseline	20/338 (5.9)	22/348 (6.3)	22/346 (6.4)		1.07 (0.53, 2.15)		1.07 (0.53, 2.17)		1.01 (0.51, 1.99)		
36 GW	2/264 (0.8)	11/291 (3.8)	11/263 (4.2)	0.07	4.99 (0.83, 29.9)	0.09	5.52 (0.92, 33.1)	0.06	1.11 (0.42, 2.95)	0.97	
IDA ^{§§}											
Baseline	36/338 (10.7)	37/348 (10.6)	37/346 (10.7)		1.00 (0.59, 1.68)		1.00 (0.60, 1.69)		1.01 (0.60, 1.68)		
36 GW	12/264 (4.5)	27/291 (9.3)	41/263 (15.6)	<0.001	2.04 (0.93, 4.49)	0.08	3.43 (1.63, 7.20)	<0.001	1.68 (0.97, 2.90)	0.07	
Elevated CRP only ^{¶‡}											
Baseline	113/338 (33.4)	108/348 (31.0)	121/346 (35.0)		0.93 (0.72, 1.20)		1.05 (0.82, 1.34)		1.13 (0.87, 1.45)		
36 GW	49/266 (18.4)	70/291 (24.1)	59/265 (22.3)	0.26	1.31 (0.89, 1.93)	0.24	1.21 (0.81, 1.81)	0.52	0.93 (0.64, 1.33)	0.87	
Elevated CRP+AGP ^{¶¶}											
Baseline	26/338 (7.7)	15/348 (4.3)	11/346 (3.2)		0.56 (0.27, 1.17)		0.41 (0.18, 0.94)		0.74 (0.30, 1.84)		
36 GW	7/266 (2.6)	9/291 (3.1)	5/265 (1.9)	0.67	1.18 (0.37, 3.77)	0.94	0.72 (0.18, 2.79)	0.83	0.61 (0.17, 2.22)	0.64	

(Continues)

Table 3. (Continued)

	IFA [†] [N = 349]	MMN [†] [N = 354]	LNS [†] [N = 354]	P [‡]	Comparison of IFA and MMN [§]		Comparison of IFA and LNS [§]		Comparison of MMN and LNS [§]		
					RR (95% CI)	P	RR (95% CI)	P	RR (95% CI)	P	
Elevated AGP only***											
Baseline	3/338 (0.9)	5/348 (1.4)	5/346 (1.4)		1.62 (0.30, 8.88)		1.63 (0.30, 8.93)		1.01 (0.23, 4.38)		
36 GW	1/266 (0.4)	0/291 (0.0)	1/265 (0.4)	1.00							

***IFA = Iron-Folic Acid group; MMN = Multiple Micronutrients group; LNS = Small Quantity Lipid-based Nutrient Supplement group. AGP, CRP, GW, Hb, IDA, TIR and ZPP are alpha-1 acid glycoprotein, C-reactive protein, gestational weeks, hemoglobin, iron deficiency anemia, transferrin receptor and zinc protoporphyrin, respectively. N = total number of participants in the group in question. †Values are number of participants positive on the variable in question/N (% of participants positive on the variable in question). ‡P-values compare all three groups, with Tukey-Kramer adjustment, using logistic regression (SAS PROC LOGISTIC). §Relative Risks, RR(95% CI) and their P-values are based on Poisson regression (Spiegelman & Hertzmark 2005). ¶Nestel & INACG Steering Committee 2002; WHO 2007; WHO/UNICEF/UNU 2001; WHO 2011. ††Hb >130 g/L (Pena-Rosas *et al.* 2012). †††ZPP >60.0 (µmol/mol heme). ††††TIR >6.0 mg/L (Pfeiffer *et al.* 2007; Vandevijvere *et al.* 2013). †††††Hb <100 g/L (WHO/UNICEF/UNU 2001; Nestel & INACG Steering Committee 2002; WHO 2007) and at least one marker of iron deficiency (ZPP >60.0 (µmol/mol heme) or TIR >6.0 mg/L (Pfeiffer *et al.* 2007; Vandevijvere *et al.* 2013)). ††††††Hb <110 g/L (WHO 2011) and at least one marker of iron deficiency (ZPP >60.0 (µmol/mol heme) or TIR >6.0 mg/L (Pfeiffer *et al.* 2007; Vandevijvere *et al.* 2013)). †††††††CRP >5.0 mg/L and AGP not >1.0 g/L (Thurnham and McCabe, 2012). ††††††††CRP not >5.0 mg/L and AGP >1.0 g/L (Thurnham and McCabe, 2012). †††††††††CRP >5.0 mg/L and AGP >1.0 g/L (Thurnham and McCabe, 2012). ††††††††††CRP >5.0 mg/L and AGP >1.0 g/L (Thurnham and McCabe, 2012).

*IFA = Iron-Folic Acid group; MMN = Multiple Micronutrients group; LNS = Small Quantity Lipid-based Nutrient Supplement group. AGP, CRP, GW, Hb, IDA, TIR and ZPP are alpha-1 acid glycoprotein, C-reactive protein, gestational weeks, hemoglobin, iron deficiency anemia, transferrin receptor and zinc protoporphyrin, respectively. N = total number of participants in the group in question. [†]Values are number of participants positive on the variable in question/N (% of participants positive on the variable in question). [‡]P-values compare all three groups, with Tukey–Kramer adjustment, using logistic regression (SAS PROC LOGISTIC). [§]Relative Risks, RR(95% CI) and their P-values are based on Poisson regression (Spiegelman & Hertzmark 2005). [¶]Nestel & INACG Steering Committee 2002; WHO 2007; WHO/UNICEF/UNU 2001. ^{||}WHO 2011. ^{|||}Hb >130 g/L (Pena-Rosas et al. 2012). ^{||||}ZPP >60.0 (μmol/mol heme). ^{|||||}TfR >6.0 mg/L (Pfeiffer et al. 2013). ^{||||||}Hb <100 g/L (WHO/UNICEF/UNU 2001; Nestel & INACG Steering Committee 2002; WHO 2007) and at least one marker of iron deficiency (ZPP >60.0 (μmol/mol heme) or TfR >6.0 mg/L (Pfeiffer et al. 2007; Vandevijvere et al. 2013)). ^{|||||||}Hb <110 g/L (WHO 2011) and at least one marker of iron deficiency (ZPP >60.0 (μmol/mol heme) or TfR >6.0 mg/L (Pfeiffer et al. 2007; Vandevijvere et al. 2013)). ^{|||||||}CRP >5.0 mg/L and AGP not >1.0 g/L (Thurnham and McCabe, 2012). ^{|||||||}CRP >5.0 mg/L and AGP >1.0 g/L (Thurnham and McCabe, 2012).

to 36 GW, the decrease in the percentage of women in the incubation phase of infection was significant for all groups. For percentage of women in early convalescence, only the decrease in the IFA group ($P=0.010$) was significant, and for percentage of women in late convalescence (where the mixed model logistic regression did not converge because of sparse data, and hence generalized estimating equations model was used), only the decrease in the MMN group ($P=0.024$) was significant.

Adjustments by covariates significantly associated with Hb and the iron status (ZPP and TfR) and inflammatory (CRP and AGP) outcomes (including the baseline value for each outcome) did not alter the unadjusted results (data not shown). In addition, correcting the Hb and iron status values for inflammation in the sensitivity analysis (results not shown) did not change the above findings.

The per-protocol analysis (results not shown) revealed that among women with adherence to treatment $\geq 70\%$ (samples sizes at 36 gestational weeks: 213 in IFA, 222 in MMN and 166 in the LNS group, for Hb), the above findings remained unchanged, except for the fact that the prevalence of anemia (defined as Hb <100 g/L or <110 g/L) did not differ between the LNS and MMN groups, and the prevalence of IDA (if definition included Hb <110 g/L) was greater only in the LNS compared with the IFA group.

Effect modification

Interactions of treatment group with BMI, season of enrolment and elevated CRP concentration at baseline were not significant for any of the outcomes. As shown in Table 4, the effect of intervention on ZPP concentration at 36 GW was modified by baseline anemia (Hb <100 g/L; P -interaction = 0.099), elevated ZPP (P -interaction = 0.013) and TfR (P -interaction = 0.090), GA at enrolment (P -interaction = 0.041), and household assets score (P -interaction = 0.061). Specifically, the difference in mean ($\pm$ SD) ZPP concentration at 36 GW among intervention groups (MMN and LNS groups compared with the IFA group) was greater among women with anemia at baseline, elevated baseline ZPP, greater GA at enrolment, or lower household assets scores. Similarly, the difference in risk of

Table 4. Effect of intervention on iron status and inflammatory outcomes of pregnant Ghanaian women, stratified by baseline characteristics*

Outcomes	IFA [†]	MMN [†]	LNS [†]	P [‡]	Comparison of MMN and IFA (n = 349)		Comparison of LNS and IFA (n = 354)		Comparison of LNS and MMN (n = 354)		
					Difference or RR	P	Difference or RR	P	Difference or RR	P	
ZPP, µmol/mol heme [§]											
Baseline anemia											
No ^{¶¶}	44 ± 2 [233]	47 ± 2 [245]	48 ± 2 [226]	0.099	0.09	3 (−2, 9)	0.34	5 (−0, 11)	0.08	2 (−4, 8)	0.71
Yes	36 ± 6 [26]	54 ± 5 [41]	53 ± 5 [33]		0.013	18 (3, 34)	0.017	18 (1, 34)	0.032	−1 (−16, 14)	0.99
Elevated baseline ZPP											
No	42 ± 2 [230]	46 ± 2 [242]	46 ± 2 [226]	0.013	0.19	3 (−2, 9)	0.34	4 (−2, 10)	0.20	1 (−5, 7)	0.94
Yes	47 ± 5 [29]	64 ± 5 [44]	72 ± 5 [33]		0.001	18 (3, 32)	0.015	25 (9, 41)	0.001	8 (−7, 22)	0.43
Elevated baseline TIR											
No	43 ± 2 [239]	47 ± 2 [261]	49 ± 2 [233]	0.090	0.06	4 (−2, 9)	0.28	6 (0, 12)	0.048	2 (−4, 8)	0.65
Yes	41 ± 6.5 [20]	63 ± 6 [25]	59 ± 6 [26]		0.017	22 (3, 41)	0.017	18 (−1, 36)	0.07	−4 (−22, 14)	0.84
GA at enrolment											
At 10 th percentile	46 ± 3	51 ± 3	44 ± 3	0.041	0.28	5 (−5, 15)	0.44	−1 (−11, 9)	0.97	−6 (−16, 4)	0.29
At 90 th percentile	40 ± 3	48 ± 3	54 ± 3		0.002	7 (−1, 16)	0.12	13 (5, 22)	0.001	6 (−3, 15)	0.25
Assets score											
At 10 th percentile	40 ± 3	46 ± 3	54 ± 3	0.061	0.003	5 (−4, 15)	0.38	14 (4, 24)	0.002	8 (−1, 18)	0.11
At 90 th percentile	46 ± 3	50 ± 3	46 ± 3		0.37	5 (−4, 13)	0.44	−0 (−9, 9)	1.00	−5 (−14, 4)	0.46
Elevated ZPP											
GA at enrolment											
At 10 th percentile ^{***}	11.1 (5.7, 20.5)	23.2 (15.3, 33.6)	11.6 (6.4, 20.0)	0.057	0.06	3.0 (0.9, 4.6)	0.12	1.0 (0.4, 2.5)	1.00	0.5 (0.2, 1.1)	0.11
At 90 th percentile	5.8 (2.9, 11.4)	14.9 (9.6, 22.3)	20.7 (14.1, 29.2)		0.004	2.4 (1.0, 5.7)	0.049	3.4 (1.5, 7.7)	0.003	1.4 (0.8, 2.5)	0.46
Elevated baseline TIR											
No ^{†††}	17/234 (7.4)	44/256 (17.4)	32/229 (14.0)	0.049	0.008	2.2 (1.2, 4.0)	0.006	1.8 (1.0, 3.4)	0.08	0.8 (0.5, 1.3)	0.61
Yes	1/20 (3.0)	3/25 (10.0)	8/25 (31.3)		0.014	1.3 (0.4, 4.6)	0.41	2.7 (0.8, 9.4)	0.016	2.1 (0.7, 6.1)	0.14
TfR, mg/L ^{**}											
Baseline anemia											
No	4.1 ± 0.1 [232]	4.5 ± 0.1 [245]	4.8 ± 0.1 [226]	0.079	<0.001	0.4 (0.1, 0.8)	0.004	0.7 (0.4, 1.0)	<0.001	0.3 (−0.0, 0.6)	0.11
Yes	3.5 ± 0.3 [26]	4.8 ± 0.3 [41]	5.0 ± 0.3 [33]		<0.001	1.3 (0.4, 2.1)	0.002	1.5 (0.6, 2.4)	<0.001	0.2 (−0.6, 1.1)	0.76
Elevated baseline AGP											
No	4.1 ± 0.1 [238]	4.6 ± 0.1 [272]	4.9 ± 0.1 [250]	0.051	<0.001	0.6 (0.3, 0.9)	<0.001	0.8 (0.5, 1.2)	<0.001	0.3 (−0.02, 0.6)	0.07
Yes	4.0 ± 0.4 [20]	4.0 ± 0.4 [14]	3.3 ± 0.5 [9]		0.503	−0.0 (−1.2, 1.2)	1.00	−0.7 (−2.1, 0.8)	0.51	−0.66 (−2.2, 0.8)	0.56
GA at enrolment											
At 10 th percentile	4.4 ± 0.2	5.0 ± 0.2	4.8 ± 0.2	0.016	0.023	0.9 (0.1, 1.1)	0.019	0.4 (−0.1, 0.9)	0.16	−0.2 (−0.7, 0.3)	0.64
(Continues)											

(Continues)

Table 4. (Continued)

Outcomes	IFA [†]	MMN [†]	LNS [†]	P [§]	Comparison of MMN and IFA (n = 349)		Comparison of LNS and IFA (n = 354)		Comparison of LNS and MMN (n = 354)	
					Difference or RR	P	Difference or RR	P	Difference or RR	P
At 90 th percentile	3.8 ± 0.1	4.3 ± 0.1	4.9 ± 0.1	<0.001	0.5 (0.0, 0.9)	0.041	1.1 (0.7, 1.6)	<0.001	0.7 (0.2, 1.1)	0.002
Elevated TIR ^{††}										
HFIA score				0.047						
At 10 th percentile	5.3 (2.9, 9.7)	15.7 (10.8, 22.2)	15.3 (10.5, 21.7)	0.004	2.3 (1.1, 4.7)	0.006	2.5 (1.2, 5.0)	0.007	1.1 (0.6, 1.8)	1.00
At 90 th percentile	9.7 (5.1, 17.5)	4.9 (1.7, 13.5)	18.7 (10.3, 31.5)	0.06	0.7 (0.2, 2.0)	0.50	1.9 (0.8, 4.6)	0.27	2.8 (0.9, 8.7)	0.06
Elevated CRP ^{‡‡}										
Elevated baseline ZPP				0.008						
No	41/225 (18.3)	72/238 (30.1)	47/221 (21.4)	0.013	1.6 (1.1, 2.4)	0.014	1.2 (0.8, 1.8)	0.71	0.7 (0.5, 1.1)	0.11
Yes	9/29 (30.1)	6/43 (13.5)	11/33 (32.0)	0.09	0.5 (0.2, 1.1)	0.17	1.1 (0.5, 2.1)	0.99	2.1 (0.9, 4.9)	0.10
Elevated AGP ^{§§}										
Assets score				0.091						
At 10 th percentile	1.0 (0.2, 4.8)	1.0 (0.2, 4.5)	2.8 (0.9, 8.4)	0.39	1.0 (0.1, 9.8)	1.00	2.8 (0.6, 14.1)	0.51	2.8 (0.3, 28.0)	0.48
At 90 th percentile	4.3 (1.5, 11.3)	4.4 (1.7, 10.8)	0.7 (0.1, 3.9)	0.14	1.0 (0.2, 4.5)	1.00	0.16 (0.0, 1.3)	0.16	0.2 (0.0, 1.4)	0.14

[†]IFA = Iron-Folic Acid group; MMN = Multiple Micronutrients group; LNS = Small Quantity Lipid-based Nutrient Supplement group. GA, Hb, HFIA, TIR and ZPP are gestation age, hemoglobin, household food insecurity access, transferrin receptor and zinc protoporphyrin, respectively. Baseline anemia is Hb <100 g/L (WHO/UNICEF/UNU 2001; Nestel & INACG Steering Committee 2002; WHO 2007). Analyses are based on ANCOVA (SAS PROC MIXED, with SLICE option) for continuous outcomes or logistic regression (SAS PROC GLIMMIX, with SLICE option) for binary outcomes. Linear regression modeling was used to predict the outcome at the 10th and 90th percentile of continuous baseline effect modifiers. [†]Values are mean ± SE [total number of participants], or mean ± SE, or percent of participants positive on the variable in question (95% CI) or number of participants positive on the variable in question/total number of participants (percent of participants positive on the variable in question). Values are adjusted for variables significantly associated with the outcome variable in bivariate analysis. [‡]P-values are for interaction with the outcome in question. [§]P-values compare all three groups in each stratum. [¶]ZPP values are adjusted for age, parity, season at enrolment and baseline Hb, ZPP and TIR concentrations. ^{‡‡}Elevated ZPP (ZPP >60 µmol/mol heme) adjusted for age, education and baseline Hb, ZPP and TIR concentrations. ^{§§}TIR values are adjusted for age, season at enrolment and baseline Hb, ZPP, TIR and AGP concentrations. ^{††}Elevated TIR (TIR >6.0 mg/L) adjusted for age, gestational age enrolment, season at enrolment and baseline Hb, ZPP and TIR concentrations. ^{‡‡}Elevated CRP (CRP >5.0 mg/L) adjusted for BMI, household food insecurity access score and baseline ZPP, AGP and CRP concentrations. ^{§§}Elevated AGP (AGP >1.0 g/L) adjusted for age, parity and season as enrolment. ^{¶¶}Values are group mean ± SE [number of participants], and difference in means (95% CI) and P-values. All such values. ^{†††}Values are group mean ± SE, and difference in means (95% CI) and P-values. All such values. ^{‡‡‡}Values are group % (95% CI), and relative risk (95% CI) and P-values. All such values. ^{††††}Values are number of participant (%), and relative risk (95% CI) and P-values. All such values.

elevated ZPP among intervention groups was greater in women with greater GA at enrolment (P -interaction=0.057), and elevated TfR at baseline (P -interaction=0.049)

The difference in mean TfR concentration at 36 GW among intervention groups was greater among women who were anemic at baseline (P -interaction=0.079), did not have elevated AGP at baseline (P -interaction=0.051), or had greater GA at enrolment (P -interaction=0.016), whereas the difference in risk of elevated TfR among intervention groups was greater in women with less food insecurity.

For elevated CRP and AGP at 36 GW, there were significant interactions between intervention group and elevated ZPP at baseline (P -interaction=0.008) and household assets score (P -interaction=0.091), but the stratified analyses (Table 4) did not show consistent results.

Discussion

In the iLiNS-DYAD-Ghana study, pregnant women who were provided with standard iron (60 mg) and folic acid supplements from ≤ 20 GW had significantly greater mean Hb, lower mean ZPP and TfR and lower prevalence of anemia and iron deficiency (elevated ZPP and TfR) at 36 GW than pregnant women who were provided with either the MMN or LNS supplements, both of which contained 20 mg iron. Overall, however, the prevalence of anemia (Hb < 100 g/L) at 36 GW was relatively low (2.2–7.9%), and iron deficiency was evident in $< 20\%$ of women in all groups. At 36 GW, the three groups did not differ in the percentage of women with high Hb (12.3% overall) or inflammation (CRP and AGP). These findings remained unchanged when analyses were restricted to women who were more adherent to treatment.

A few weaknesses of our study were described previously (Adu-Afarwuah *et al.* 2015), namely: (1) a fully double-blind study design was not possible because of the physical differences between the SQ-LNS in the form of sachets, and the other two supplements (MMN and IFA) in the form of capsules, and (2) adherence to treatment was assessed by self-report and

not direct observation. However, none of the individuals involved in sample collection, laboratory measurements or data analysis had any knowledge of group assignment. The good collaboration with the antenatal clinics (which gave women the confidence to cooperate), relatively low rate of attrition, intense follow-up of participants and detailed attention we paid to ensuring data quality were notable strengths of the study.

Several possible explanations may be relevant for the observed lower Hb and higher ZPP and TfR values in the MMN and LNS groups compared with the IFA group. First, the 20-mg iron dose used in the MMN and LNS supplements may have been too low for this Ghanaian population of pregnant women. In most (but not all) similar studies, the iron dose of the iron + folic acid supplement was 60 mg/day and that of the multiple micronutrient supplement was 30 mg/day (Allen & Pearson 2009; Roberfroid *et al.* 2011; Mei *et al.* 2014), although in Indonesia (Suprpto *et al.* 2002), Mexico (Ramakrishnan *et al.* 2004), Nepal (Christian *et al.* 2003) and Tanzania (Makola *et al.* 2003), both the iron + folic acid and multiple micronutrient supplement groups received iron doses of at least 50 mg/day. In these studies (even for those that used multiple micronutrients containing 30-mg Fe), pregnant women consuming the multiple micronutrient supplements generally did not differ in Hb or iron status indicators compared with those consuming iron + folic acid (Allen & Pearson 2009; Roberfroid *et al.* 2011; Mei *et al.* 2014). A study of Australian women (Zhou *et al.* 2009) suggested that 20-mg iron per day may be an adequate dose to prevent IDA during pregnancy compared with higher doses of iron. However, the diet of the women in our sample, as is typical of Ghana, is mainly plant-based and high in phytate (Gibson 1994), which reduces iron absorption (Baech *et al.* 2003), so dietary iron needs during pregnancy may be higher in Ghana than in Australia.

Another possibility is that the relatively high dose of zinc (30 mg) in the MMN and LNS supplements may have interfered with iron absorption, as suggested by the results of a supplementation trial in Nepal (Christian *et al.* 2003). The lack of a good biomarker of zinc status at the individual level makes it difficult to explore this potential mechanism for the differences in iron status between the IFA and other two groups.

It is noteworthy that there were no significant differences in mean Hb or iron status between the LNS and MMN groups, despite the fact that SQ-LNS is a food-based supplement rather than a capsule and some differences in composition could have affected these outcomes. For instance, it is possible that the calcium or phytate in SQ-LNS could have limited the absorption of iron in the LNS group. The lack of differences in Hb and iron status between these two groups suggests that the iron or other micronutrient content (which was identical in these two supplements, except for the macro-minerals) was the most critical factor.

In Ghana, anemia (Ghana Statistical Service (GSS), Ghana Health Service (GHS), & ICF Macro (2009)) and infections including malaria (Yatich *et al.* 2009) are common among pregnant women even in relatively high income communities, and evidence (Mockenhaupt *et al.* 2000) suggests that malaria is a major risk factor for anemia. Thus, it is noteworthy that the prevalence of both anemia and elevated CRP declined significantly in all three groups between baseline and 36-week gestation.

It is important to consider the implications of the observed lower mean Hb of the SQ-LNS and MMN groups compared with the IFA group at 36-week gestation. Low Hb concentration or anemia in the first or second trimester of pregnancy is linked with poor pregnancy outcomes including low birth weight (Murphy *et al.* 1986), but no such association has been established for low Hb concentration or anemia in the third trimester (Allen 2000). Further, Hb concentrations substantially above 110–119 g/L during pregnancy may be independent of iron status and have been linked with poorer health outcomes for the mother and fetus (Zhou *et al.* 1998; Yip 2000). Therefore, the higher mean Hb concentrations observed for women in the IFA group compared with those in the LNS and MMN groups in the third trimester (36 GW) may not necessarily be beneficial with respect to birth outcomes. In fact, we previously demonstrated that in this same study (Adu-Afarwuah *et al.* 2015) the prenatal consumption of LNS (compared with IFA) was associated with greater birth weight, weight-for-age z-score and BMI-for-age z-score, and that, in first-time mothers, prenatal LNS supplementation also increased birth length and head circumference and reduced the

proportion of infants with low birth weight, low birth length and small-for-gestational age. In this cohort, there was no relationship between Hb at 36-week gestation and infant birth size, and there was actually a significant *negative* relationship between maternal iron status at 36 wk and birth size (Oaks *et al.* 2015). Thus, the difference between the LNS and IFA groups in mean maternal Hb, ZPP and TfR concentrations needs to be weighed against the difference (in the opposite direction) in birth outcomes. In two sets of analyses (Garn *et al.* 1981; Steer *et al.* 1995) each involving a large number of pregnant women, the lowest risk of adverse birth outcomes including low birth weight was seen in women with Hb ~95–105 g/L (Steer *et al.* 1995) or Hb ~100–110 g/L (Garn *et al.* 1981). Appropriate cut-offs for ZPP and TfR in pregnancy are not well documented, particularly with respect to functional outcomes. Therefore, it is difficult to judge whether our results should be interpreted as ‘improvements’ in maternal iron status in the IFA group compared with the MMN or LNS group.

We conclude that among pregnant women in a semi-urban setting in Ghana, supplementation with SQ-LNS or MMN containing 20 mg iron resulted in lower Hb and iron status but had no impact on inflammation, when compared with iron (60 mg) plus folic acid (400 µg) treatment. The amount of iron in such supplements that is most effective for improving both maternal Hb/iron status and birth outcomes requires further evaluation.

Trial registration

ClinicalTrials.gov, Identifier NCT00970866

Acknowledgements

We thank the families of the study subjects for their participation and cooperation; Maku Ocansey, Seth Antwi, Ronnie Osei-Boateng and Boateng Bannerman for contribution to data collection and management; Janet M. Peerson for assisting with data analysis and SAS programming; Mary Arimond for comments and

suggestions; iLiNS Steering Committee members Kenneth H Brown, Kenneth Maleta and Jean Bosco Ouedraogo for advice in trial conceptualization; and Lindsay Allen for helping to define the SQ-LNS formulation and for input at various stages.

Source of funding

Funded by a grant to the University of California, Davis from the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Contributions

SA-A, AL, PA, MZ, SV and KGD designed the research; MZ was responsible for the development and production of the LNS used in the study based on the specifications agreed upon by the iLiNS Project; SA-A, AL and HO conducted the research; LMB and BO performed laboratory analysis; SA-A performed the statistical analysis; AL, PA and KGD advised on the analysis; SA-A and KGD wrote the manuscript; and AL, HO, PA, MZ, LMB, BO and SV reviewed the draft manuscript. All authors read and approved the final manuscript.

Abbreviations

AGP, Alpha-1 glycoprotein; CRP, C-reactive protein; EFA, Essential fatty acid; GA, Gestational age; GW, Gestational weeks; IDA, Iron deficiency anemia; IFA, Iron and folic acid; LNS, Lipid-based nutrient supplement; MMN, Multiple micronutrients;

SQ-LNS, Small-quantity lipid-based nutrient supplement; TfR, Transferrin receptor; ZPP, Zinc protoporphyrin.

References

- Adu-Afarwuah S., Lartey A., Okronipa H., Ashorn P., Zeilani M., Pearson J.M. *et al.* (2015) Lipid-based nutrient supplement increases the birth size of infants of primiparous women in Ghana. *The American Journal of Clinical Nutrition* **101**, 835–846.
- Allen L.H. (2000) Anemia and iron deficiency: effects on pregnancy outcome. *The American Journal of Clinical Nutrition* **71**, 1280S–1284S.
- Allen L.H. & Pearson J.M. (2009) Impact of multiple micronutrient versus iron-folic acid supplements on maternal anemia and micronutrient status in pregnancy. *Food and Nutrition Bulletin* **30**, S527–532.
- Arimond M., Zeilani M., Jungjohann S., Brown K.H., Ashorn P., Allen L.H. *et al.* (2013) Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. *Maternal & Child Nutrition*.
- Baech S.B., Hansen M., Bukhave K., Jensen M., Sorensen S.S., Kristensen L. *et al.* (2003) Nonheme-iron absorption from a phytate-rich meal is increased by the addition of small amounts of pork meat. *The American Journal of Clinical Nutrition* **77**, 173–179.
- Bertran N., Camps J., Fernandez-Ballart J., Arijia V., Ferre N., Tous M. *et al.* (2005) Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. *Journal of Laboratory and Clinical Medicine* **145**, 41–46.
- Brighenti F., Valtuena S., Pellegrini N., Ardigo D., Del Rio D., Salvatore S. *et al.* (2005) Total antioxidant capacity of the diet is inversely and independently related to plasma concentration of high-sensitivity C-reactive protein in adult Italian subjects. *The British Journal of Nutrition* **93**, 619–625.
- van den Broek N.R., Letsky E.A., White S.A. & Shenkin A. (1998) Iron status in pregnant women: which measurements are valid? *The British Journal of Haematology* **103**, 817–824.
- Christian P., Shrestha J., LeClerq S.C., Khatry S.K., Jiang T., Wagner T. *et al.* (2003) Supplementation with micronutrients in addition to iron and folic acid does not further improve the hematologic status of pregnant women in rural Nepal. *The Journal of Nutrition* **133**, 3492–3498.
- Coates J., Swindale A. & Bilinsky P. (2007) Household Food Insecurity Access Scale (HFIAS) for Measurement of Food Access: Indicator Guide (V.3) [Internet]. Food and Nutrition Technical Assistance Project, Academy for Educational Development, Washington, D.C [cited 2013 Aug 12]. Available from: http://www.fao.org/fileadmin/user_upload/eufao-fsi4dm/doc-training/hfiass.pdf.

- Cohen J. (1988) *Statistical Power Analysis in the Behavioral Sciences*, 2nd edn. Lawrence Erlbaum Associates, Inc.: Hillsdale (NJ).
- Devaraj S. & Jialal I. (2000) Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. *Journal of Free Radicals in Biology & Medicine* **29**, 790–792.
- Elovitz M.A. (2006) Anti-inflammatory interventions in pregnancy: now and the future. *Seminars in Fetal & Neonatal Medicine* **11**, 327–332.
- Fall C.H., Fisher D.J., Osmond C. & Margetts B.M. (2009) Multiple micronutrient supplementation during pregnancy in low-income countries: a meta-analysis of effects on birth size and length of gestation. *Food and Nutrition Bulletin* **30**, S533–S546.
- Friso S., Jacques P.F., Wilson P.W.F., Rosenberg I.H. & Selhub J. (2001) Low circulating vitamin B6 is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. *Circulation* **103**, 2788–2791.
- Garn S.M., Keating M.T. & Falkner F. (1981) Hematological status and pregnancy outcomes. *The American Journal of Clinical Nutrition* **34**, 115–117.
- Ghana Statistical Service (GSS), Ghana Health Service (GHS) & ICF Macro (2009) *Ghana Demographic and Health Survey 2008*. GSS, GHS, and ICF Macro: Accra, Ghana.
- Gibson R.S. (1994) Zinc nutrition in developing countries. *Nutrition Research Reviews* **7**, 151–173.
- Grant F.K., Suchdev P.S., Flores-Ayala R., Cole C.R., Ramakrishnan U., Ruth L.J. et al. (2012) Correcting for inflammation changes estimates of iron deficiency among rural Kenyan preschool children. *The Journal of Nutrition* **142**, 105–111.
- Haider B.A. & Bhutta Z.A. (2012) Multiple-micronutrient supplementation for women during pregnancy. *The Cochrane Database of Systematic Reviews* **11**, CD004905.
- Haider B.A., Yakoob M.Y. & Bhutta Z.A. (2011) Effect of multiple micronutrient supplementation during pregnancy on maternal and birth outcomes. *BMC Public Health* **11** (Suppl 3), S19.
- Haider B.A., Olofin I., Wang M., Spiegelman D., Ezzati M., Fawzi W.W. et al. (2013) Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. *BMJ* **346**, f3443.
- Hambidge K.M., Krebs N.F., Westcott J.E., Garces A., Goudar S.S., Kodkany B.S. et al. (2014) Preconception maternal nutrition: a multi-site randomized controlled trial. *BMC Pregnancy & Childbirth* **14**, 111.
- Imdad A. & Bhutta Z.A. (2012) Routine iron/folate supplementation during pregnancy: effect on maternal anaemia and birth outcomes. *Paediatric and Perinatal Epidemiology* **26** (Suppl 1), 168–177.
- International Anemia Consultative Group (INACG) (2002) Report of the 2001 International Anemia Consultative Group Symposium. Why is iron important and what to do about it: a new perspective. Washington, DC, INACG Secretariat.
- IOM (2001) *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc*. National Academy Press: Washington, DC.
- Kaestel P., Michaelsen K.F., Aaby P. & Friis H. (2005) Effects of prenatal multimicronutrient supplements on birth weight and perinatal mortality: a randomised, controlled trial in Guinea-Bissau. *The European Journal of Clinical Nutrition* **59**, 1081–1089.
- Makola D., Ash D.M., Tatala S.R., Latham M.C., Ndossi G. & Mehansho H. (2003) A micronutrient-fortified beverage prevents iron deficiency, reduces anemia and improves the hemoglobin concentration of pregnant Tanzanian women. *The Journal of Nutrition* **133**, 1339–1346.
- Mei Z., Serdula M.K., Liu J.M., Flores-Ayala R.C., Wang L., Ye R. et al. (2014) Iron-containing micronutrient supplementation of Chinese women with no or mild anemia during pregnancy improved iron status but did not affect perinatal anemia. *The Journal of Nutrition* **144**, 943–948.
- Michaelsen K.F., Dewey K.G., Perez-Exposito A.B., Nurhasan M., Lauritzen L. & Roos N. (2011) Food sources and intake of n-6 and n-3 fatty acids in low-income countries with emphasis on infants, young children (6–24 months), and pregnant and lactating women. *Maternal & Child Nutrition* **7** (Suppl 2), 124–140.
- Mockenhaupt F.P., Rong B., Günther M., Beck S., Till H., Kohne E. et al. (2000) Anaemia in pregnant Ghanaian women: importance of malaria, iron deficiency, and haemoglobinopathies. *Transaction of the Royal Society of Tropical Medicine & Hygiene* **94**, 477–483.
- Murphy J.F., O’Riordan J., Newcombe R.G., Coles E.C. & Pearson J.F. (1986) Relation of haemoglobin levels in first and second trimesters to outcome of pregnancy. *Lancet* **1**, 992–995.
- Nestel P. & INACG Steering Committee (2002) Adjusting hemoglobin values in program surveys [Internet]. INACG, Washington, DC [cited 2014-Jan 10]. Available from: http://pdf.usaid.gov/pdf_docs/PNACQ927.pdf.
- Oaks B., Stewart C., Laugero K., Adu-Afarwuah S., Lartey A., Baldiviez L. et al. (2015) Associations of maternal cortisol, inflammation, hemoglobin, iron status, and BMI with birth outcomes in pregnant women in Ghana. *The Federation of American Societies for Experimental Biology Journal* **29**.
- Pena-Rosas J.P., De-Regil L.M., Dowswell T. & Viteri F.E. (2012) Daily oral iron supplementation during pregnancy. *The Cochrane Database of Systematic Reviews* **12**, CD004736.
- Pfeiffer C.M., Cook J.D., Mei Z., Cogswell M.E., Looker A.C. & Lacher D.A. (2007) Evaluation of an automated soluble transferrin receptor (sTfR) assay on the Roche Hitachi analyzer and its comparison to two ELISA assays. *Clinica Chimica Acta: International Journal of Clinical Chemistry* **382**, 112–116.

- Picklesimer A.H., Jared H.L., Moss K., Offenbacher S., Beck J. D. & Bogges K.A. (2008) Racial differences in C-reactive protein levels during normal pregnancy. *American Journal of Obstetrics and Gynecology* **199**, 523.e521–523.e526.
- Rallidis L.S., Paschos G., Liakos G.K., Velissaridou A.H., Anastasiadis G. & Zampelas A. (2003) Dietary α -linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. *Atherosclerosis* **167**, 237–242.
- Ramakrishnan U., Neufeld L.M., Gonzalez-Cossio T., Villalpando S., Garcia-Guerra A., Rivera J. *et al.* (2004) Multiple micronutrient supplements during pregnancy do not reduce anemia or improve iron status compared to iron-only supplements in Semirural Mexico. *The Journal of Nutrition* **134**, 898–903.
- Ramakrishnan U., Grant F.K., Goldenberg T., Bui V., Imdad A. & Bhutta Z.A. (2012) Effect of multiple micronutrient supplementation on pregnancy and infant outcomes: a systematic review. *Paediatric and Perinatal Epidemiology* **26** (Suppl 1), 153–167.
- Ren A., Wang J., Ye R.W., Li S., Liu J.M. & Li Z. (2007) Low first-trimester hemoglobin and low birth weight, preterm birth and small for gestational age newborns. *International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics* **98**, 124–128.
- Research Engagement on Food Innovation for Nutritional Effectiveness (REFINE) (2013) Ongoing studies using Lipid Based Nutrient Supplement (LNS) [Internet]. REFINE. Boston, MA. [cited 2015 Jun 23]. Available from: <http://refinenutrition.org/research/REFINE-product-LNS.pdf>.
- Roberfroid D., Huybrechts L., Habicht J.P., Lanou H., Henry M.C., Meda N. *et al.* (2011) Randomized controlled trial of 2 prenatal iron supplements: is there a dose–response relation with maternal hemoglobin? *The American Journal of Clinical Nutrition* **93**, 1012–1018.
- Roberts J.M., Balk J.L., Bodnar L.M., Belizán J.M., Bergel E. & Martinez A. (2003) Nutrient involvement in preeclampsia. *The Journal of Nutrition* **133**, 1684S–1692S.
- Sacks G.P., Studena K., Sargent I.L. & Redman C.W.G. (1998) Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. *American Journal of Obstetrics and Gynecology* **179**, 80–86.
- Spiegelman D. & Hertzmark E. (2005) Easy SAS calculations for risk or prevalence ratios and differences. *American Journal of Epidemiology* **162**, 199–200.
- Steer P., Alam M.A., Wadsworth J. & Welch A. (1995) Relation between maternal haemoglobin concentration and birth weight in different ethnic groups. *BMJ* **310**, 489–491.
- Suprpto B., Widardo & Suhanantyo (2002) Effect of low-dosage vitamin A and riboflavin on iron-folate supplementation in anaemic pregnant women. *Asia Pacific Journal Clinical Nutrition* **11**, 263–267.
- Tatala S., Svanberg U. & Mduma B. (1998) Low dietary iron availability is a major cause of anemia: a nutrition survey in the Lindi District of Tanzania. *The American Journal of Clinical Nutrition* **68**, 171–178.
- Thurnham D.I. & McCabe G.P. (2012) Influence of infection and inflammation on biomarkers of nutritional status with an emphasis on vitamin A and iron. In: World Health Organization. Report: Priorities in the assessment of vitamin A and iron status in populations, Panama City, Panama, 15–17 September 2010 [Internet]. World Health Organization, Geneva [cited 2014 Nov 14]. Available from: http://www.who.int/nutrition/publications/micronutrients/background_paper4_report_assessment_vitAandIron_status.pdf.
- UNICEF/WHO/UNU (1999) Composition of a multi-micronutrient supplement to be used in pilot programmes among pregnant women in developing countries [Internet]. New York: UNICEF [cited 2015 Jan 18]. Available from: <http://apps.who.int/iris/bitstream/10665/75358/1/UNICEF-WHO-multi-micronutrients.pdf?ua=1>.
- Vandevijvere S., Amsalkhir S., Van Oyen H., Egli I. & Moreno-Reyes R. (2013) Iron status and its determinants in a nationally representative sample of pregnant women. *Journal of the Academy of Nutrition and Dietetics* **113**, 659–666.
- Walsh T., O'Broin S.D., Cooley S., Donnelly J., Kennedy J., Harrison R.F. *et al.* (2011) Laboratory assessment of iron status in pregnancy. *Clinical Chemistry and Laboratory Medicine: CCLM/FESCC* **49**, 1225–1230.
- WHO (2007) Assessing the iron status of populations: Report of a joint World Health Organization/Centers for Disease Control and Prevention technical consultation on the assessment of iron status at the population level, 2nd Ed. [Internet]. World Health Organization, Geneva [cited 2015 Oct 22]. Available from: http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/9789241596107.pdf
- WHO (2011) Hemoglobin concentrations for the diagnosis of anemia and assessment of severity [Internet]. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization (WHO/NMH/NHD/MNM/11.1) [cited 2015 Oct 21]. Available from: <http://www.who.int/vmnis/indicators/haemoglobin.pdf>.
- WHO (2012) Guideline: Daily iron and folic acid supplementation in pregnant women [Internet]. World Health Organization, Geneva; 2012 [cited 2014 Jul 13]. Available from: http://apps.who.int/iris/bitstream/10665/77770/1/9789241501996_eng.pdf?ua=1.
- WHO/UNICEF/UNU (2001) Iron deficiency anaemia assessment, prevention, and control: a guide for programme managers. WHO/NHD/01.3. [Internet]. World Health Organization, Geneva [cited 2014 Dec 01]. Available from: http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf.
- World Health Organization (1992) The prevalence of anaemia in women. WHO/MCH/MSM/92.2.

- Yatich N.J., Yi J., Agbenyega T., Turpin A., Rayner J.C., Stiles J.K. *et al.* (2009) Malaria and intestinal helminth co-infection among pregnant women in Ghana: prevalence and risk factors. *The American Journal of Tropical Medicine and Hygiene* **80**, 896–901.
- Yip R. (2000) Significance of an abnormally low or high hemoglobin concentration during pregnancy: special consideration of iron nutrition. *The American Journal of Clinical Nutrition* **72**, 272S–279S.
- Zhou L.-M., Yang W.-W., Hua J.-Z., Deng C.-Q., Tao X. & Stoltzfus R.J. (1998) Relation of hemoglobin measured at different times in pregnancy to preterm birth and low birth weight in Shanghai, China. *American Journal of Epidemiology* **148**, 998–1006.
- Zhou S.J., Gibson R.A., Crowther C.A. & Makrides M. (2009) Should we lower the dose of iron when treating anaemia in pregnancy? A randomized dose–response trial. *European Journal of Clinical Nutrition* **63**, 183–190.